Miranda Merrill1, Nancy K Sweitzer2, JoAnn Lindenfeld3, David P Kao4. 1. Department of Internal Medicine, University of Colorado School of Medicine, Aurora, Colorado. 2. Division of Cardiology, Sarver Heart Center, University of Arizona College of Medicine, Tucson, Arizona. 3. Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Vanderbilt Heart and Vascular Institute, Nashville, Tennessee. 4. Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado. Electronic address: David.Kao@ucdenver.edu.
Abstract
OBJECTIVES: This study sought to investigate sex differences in outcomes and responses to spironolactone in patients with heart failure with preserved ejection fraction (HFpEF). BACKGROUND:HFpEF affects women more frequently than men. Sex differences in responses to effects of mineralocorticoid antagonists have not been reported. METHODS: This was an exploratory, post hoc, non-pre-specified analysis of the TOPCAT (Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function) trial. Subjects with symptomatic HF and a left ventricular ejection fraction ≥45% were randomized to spironolactone or placebo therapy. Subjects enrolled from the Americas were analyzed. The primary outcome was a composite of cardiovascular (CV) death, cardiac arrest, or HF hospitalization. Secondary outcomes included all-cause mortality, CV, and non-CV mortality and CV, HF, and non-CV hospitalization. Sex differences in outcomes and treatment effects were determined using time-to-event analysis. RESULTS:In total, 882 of 1,767 subjects (49.9%) were women. Women were older with fewer comorbidities but worse patient-reported outcomes. There were no sex differences in outcomes in the placebo arm or in response to spironolactone for the primary outcome or its components. Spironolactone therapy was associated with reduced all-cause mortality in women (hazard ratio: 0.66; p = 0.01) but not in men (pinteraction = 0.02). CONCLUSIONS: In TOPCAT, women and men presented with different clinical profiles and similar clinical outcomes. The interaction between spironolactone and sex in TOPCAT overall and in the present analysis was nonsignificant for the primary outcome, but there was a reduction in all-cause mortality associated with spironolactone therapy in women, with a significant interaction between sex and treatment arm. Prospective evaluation is needed to determine whether spironolactone therapy may be effective for treatment of HFpEF in women. (Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function [TOPCAT]; NCT00094302).
RCT Entities:
OBJECTIVES: This study sought to investigate sex differences in outcomes and responses to spironolactone in patients with heart failure with preserved ejection fraction (HFpEF). BACKGROUND:HFpEF affects women more frequently than men. Sex differences in responses to effects of mineralocorticoid antagonists have not been reported. METHODS: This was an exploratory, post hoc, non-pre-specified analysis of the TOPCAT (Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function) trial. Subjects with symptomatic HF and a left ventricular ejection fraction ≥45% were randomized to spironolactone or placebo therapy. Subjects enrolled from the Americas were analyzed. The primary outcome was a composite of cardiovascular (CV) death, cardiac arrest, or HF hospitalization. Secondary outcomes included all-cause mortality, CV, and non-CV mortality and CV, HF, and non-CV hospitalization. Sex differences in outcomes and treatment effects were determined using time-to-event analysis. RESULTS: In total, 882 of 1,767 subjects (49.9%) were women. Women were older with fewer comorbidities but worse patient-reported outcomes. There were no sex differences in outcomes in the placebo arm or in response to spironolactone for the primary outcome or its components. Spironolactone therapy was associated with reduced all-cause mortality in women (hazard ratio: 0.66; p = 0.01) but not in men (pinteraction = 0.02). CONCLUSIONS: In TOPCAT, women and men presented with different clinical profiles and similar clinical outcomes. The interaction between spironolactone and sex in TOPCAT overall and in the present analysis was nonsignificant for the primary outcome, but there was a reduction in all-cause mortality associated with spironolactone therapy in women, with a significant interaction between sex and treatment arm. Prospective evaluation is needed to determine whether spironolactone therapy may be effective for treatment of HFpEF in women. (Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function [TOPCAT]; NCT00094302).
Authors: Sheila M Hegde; Brian Claggett; Amil M Shah; Eldrin F Lewis; Inder Anand; Sanjiv J Shah; Nancy K Sweitzer; James C Fang; Bertram Pitt; Marc A Pfeffer; Scott D Solomon Journal: Circulation Date: 2017-06-21 Impact factor: 29.690
Authors: Simon de Denus; Eileen O'Meara; Akshay S Desai; Brian Claggett; Eldrin F Lewis; Grégoire Leclair; Martin Jutras; Joël Lavoie; Scott D Solomon; Bertram Pitt; Marc A Pfeffer; Jean L Rouleau Journal: N Engl J Med Date: 2017-04-27 Impact factor: 91.245
Authors: Senthil Selvaraj; Brian Claggett; Sanjiv J Shah; Inder Anand; Jean L Rouleau; Akshay S Desai; Eldrin F Lewis; Bertram Pitt; Nancy K Sweitzer; Marc A Pfeffer; Scott D Solomon Journal: Eur J Heart Fail Date: 2017-11-16 Impact factor: 15.534
Authors: Bertram Pitt; Marc A Pfeffer; Susan F Assmann; Robin Boineau; Inder S Anand; Brian Claggett; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Brian Harty; John F Heitner; Christopher T Kenwood; Eldrin F Lewis; Eileen O'Meara; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Song Yang; Sonja M McKinlay Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245
Authors: Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin Journal: N Engl J Med Date: 2003-03-31 Impact factor: 91.245
Authors: Ramachandran S Vasan; Jane C Evans; Emelia J Benjamin; Daniel Levy; Martin G Larson; Johan Sundstrom; Joanne M Murabito; Flora Sam; Wilson S Colucci; Peter W F Wilson Journal: Hypertension Date: 2004-03-08 Impact factor: 10.190
Authors: Rosemeire M Kanashiro-Takeuchi; Bettina Heidecker; Guillaume Lamirault; Jennifer W Dharamsi; Joshua M Hare Journal: Clin Transl Sci Date: 2009-04 Impact factor: 4.689
Authors: T Rajendra Kumar; Jane E B Reusch; Wendy M Kohrt; Judith G Regensteiner Journal: J Womens Health (Larchmt) Date: 2020-05-17 Impact factor: 2.681
Authors: Tim Lahm; Edward Hess; Anna E Barón; Thomas M Maddox; Mary E Plomondon; Gaurav Choudhary; Bradley A Maron; Roham T Zamanian; Peter J Leary Journal: Chest Date: 2020-10-05 Impact factor: 9.410
Authors: Mengyun Lu; Li-Yuan Chen; Salina Gairhe; Adrien J Mazer; Stasia A Anderson; Jasmine N H Nelson; Audrey Noguchi; Mohammad Abdul Hai Siddique; Edward J Dougherty; Yvette Zou; Kathryn A Johnston; Zu-Xi Yu; Honghui Wang; Shuibang Wang; Junfeng Sun; Steven B Solomon; Rebecca R Vanderpool; Michael A Solomon; Robert L Danner; Jason M Elinoff Journal: Am J Physiol Lung Cell Mol Physiol Date: 2022-01-19 Impact factor: 5.464